A single-domain antibody of glypican 3 and its application

By screening and fusing GPC3 single-domain antibodies with human immunoglobulin Fc fragments, the problems of large molecular weight and weak permeability of existing GPC3 antibodies in tumor treatment were solved, achieving efficient and specific recognition and enhanced tumor treatment effects.

CN119798446BActive Publication Date: 2025-09-12GUANGZHOU BIOSYNGEN CO LTD
3 Cites 0 Cited by

Patent Information

Application Number
CN202510016490.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2025-01-06
Publication Date
2025-09-12
Estimated Expiration
2045-01-06

AI Technical Summary

Technical Problem

Existing GPC3 antibodies have problems in tumor targeted therapy, such as large molecular weight, weak tissue penetration, and strong immunogenicity, making it difficult to effectively bind to the GPC3 protein on the surface of tumor cells.

Method used

Alpacas were immunized with CHO-S cells overexpressing GPC3, and a phage display library was constructed. Single-domain antibodies against glypican 3 with good specificity and affinity were screened and fused with the human immunoglobulin Fc fragment to develop small molecular weight recombinant antibodies.

Benefits of technology

It achieves efficient binding and specific recognition of GPC3 protein, improves the effectiveness of antibodies in tumor diagnosis and treatment, and enhances the tissue penetration of drugs and the killing ability of immune cells.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention relates to a glypican 3 single-domain antibody and its application. The amino acid sequence of CDR1 of the single-domain antibody includes the sequence shown in SEQ ID NO.1, the amino acid sequence of CDR2 includes the sequence shown in SEQ ID NO.2, and the amino acid sequence of CDR3 includes the sequence shown in SEQ ID NO.3. The present invention utilizes eukaryotically expressed GPC3 fusion protein to immunize camels, construct a phage display library, and screen to obtain glypican 3 single-domain antibodies with good specificity and affinity. At the same time, they have the characteristics of low molecular weight, which can effectively develop therapeutic drugs, engineered immune cells, and detection reagents.
Need to check novelty before this filing date? Find Prior Art